Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 3/20 | 0.40 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.39 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.38 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | BTK | Q06187 | 1/20 | 0.38 |
| ▸ | PPARG | P37231 | 1/20 | 0.38 |
| ▸ | PPARD | Q03181 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.38 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.38 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | PRKACA | P17612 | 1/20 | 0.37 |
| ▸ | GSK3A | P49840 | 1/20 | 0.37 |
| ▸ | GSK3B | P49841 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6482834 | 0.79 | PDE4A (0.52) | CHRM4EPHX2PPARGPPARDPPARA | |
| SCHEMBL6500806 | 0.77 | PTGER4 (0.42) | DGAT2EPHX2PPARGPPARDPPARA | |
| SCHEMBL6483362 | 0.76 | NPC1 (0.51) | CHRM4MAPK8CYP3A4CYP2D6 | |
| SCHEMBL6474340 | 0.76 | AR (0.39) | CHRM4EPHX2NR1H4NR3C1HSD17B13 | |
| SCHEMBL6483657 | 0.75 | HSD17B13 (0.38) | DGAT2EPHX2MAPK8NR1H4NR3C1 | |
| SCHEMBL6475043 | 0.75 | MMP13 (0.41) | CHRM4ROCK2ROCK1 | |
| SCHEMBL6477125 | 0.73 | PDE4A (0.51) | EPHX2PPARGPPARDPPARAHSD17B13 | |
| SCHEMBL6475852 | 0.73 | PDE4A (0.48) | — | |
| SCHEMBL6482838 | 0.72 | EPHX2 (0.35) | CHRM4EPHX2PPARGPPARDPPARA | |
| SCHEMBL6486741 | 0.72 | PDE4A (0.51) | CHRM4EPHX2NR1H4HSD17B13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1355907-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | Pfizer Products Inc. (US) | 2003-10-29 | — | — | EP | claimed |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-10-02 | — | — | US | claimed |
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | MARFAT ANTHONY (US) | 2003-07-10 | — | — | US | claimed |
| US-6559168-B2 | 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-05-06 | — | — | US | claimed |
| US-20020123520-A1 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC. | 2002-09-05 | — | — | US | claimed |
| WO-2002060898-A1 | THIAZOLYL-, OXAZOLYL-, PYRROLYL-, AND IMIDAZOLYL-ACID AMIDE DERIVATIVES USEFUL AS INHIBITORS OF PDE4 ISOZYMES | PFIZER PRODUCTS INC. (US) | 2002-08-08 | — | — | WO | claimed |
| US-6894041-B2 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-05-17 | — | — | US | disclosed |
| US-6869945-B2 | Pyrrolyl-and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | PFIZER INC (US) | 2005-03-22 | — | — | US | disclosed |
| US-6559168-B2 | 3',5'-cyclic nucleotide phosphodiesterases (PDEs); disease related to eosinophils, such as asthma, chronic bronchitis, and chronic obstructuive pulmonary disease | PFIZER INC | 2003-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130254-A1 | Oxazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, NOX1, NOX3 | DGAT2 2003/4885CHRM4 177/4885AKR1C3 114/4885 |
| US-20020123520-A1 | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, CBR3, PDE4A | DGAT2 3092/4885CHRM4 158/4885AKR1C3 124/4885 |
| US-20030186974-A1 | Pyrrolyl- and imidazolyl-acid amide derivatives useful as inhibitors of PDE4 isozymes | CBR1, PDE4A, PDE3B | DGAT2 2669/4885CHRM4 154/4885AKR1C3 141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.